未经证实:质子泵抑制剂(PPI)和H2受体阻滞剂是治疗胃和小肠上部溃疡的常用处方药,并用于治疗其他一些常见的胃肠道并发症,如胃食管反流病,食管炎,肠易激综合征,和消化不良.以前的研究声称,除了其他副作用,这些抗溃疡疗法通过干扰肠道矿物质和维生素B12的重吸收而显著改变了骨矿物质密度,而最广泛使用的PPI与髋部和脊柱骨折风险增加显著相关.然而,这些抗溃疡药的潜在骨骼副作用在孟加拉国尚不清楚.
UNASSIGNED:为了研究孟加拉国患者抗溃疡治疗的安全性问题及其对肌肉骨骼健康的影响,本研究调查了2019年12月至2020年2月5家不同医院的200名患者.
UNASSIGNED:当前的研究表明,大多数受访者(95%)接受PPI用于胃肠道适应症,而其余受访者则服用H2受体拮抗剂用于胃病。大多数患者单独服用PPI(>3年;95%的受访者)声称一些不寻常的肌肉骨骼副作用,比如软弱,侧腹疼痛,手和脚的痉挛,肌肉疼痛,麻木,和震颤。服用PPI的患者中约有61%出现腰背痛,而颈部疼痛和膝关节疼痛的受访者分别为10%和7%。分别。然而,骨量减少和骨质疏松的发生率也很少。虽然需要进一步的研究来证实这些抗溃疡剂对骨骼的影响,这些患者的反应表明,这些肌肉骨骼副作用可能与骨代谢改变有关。
未经评估:抗溃疡治疗可能会使患有骨质疏松症或其他骨骼疾病的患者的骨骼代谢恶化,应提高患者和临床医生对患有骨骼疾病的患者谨慎使用PPI的认识和预防措施。
UNASSIGNED: Proton pump inhibitors (PPIs) and H2 blockers are commonly prescribed medications to treat ulcers in the stomach and the upper part of the small intestine and prescribed for some other common gastrointestinal complications such as gastroesophageal reflux disease, esophagitis, irritable bowel syndrome, and dyspepsia. Previous studies claimed that, apart from other side effects, these anti-ulcerant therapies significantly altered bone mineral density by interfering with intestinal reabsorption of minerals and vitamin B12, and the most widely prescribed PPIs were significantly associated with increased risks of hip and spine fractures. However, the potential skeletal side effects of these antiulcerants are unknown in Bangladesh.
UNASSIGNED: To examine safety concerns of anti-ulcer therapies and their impact on musculoskeletal health among patients in Bangladesh, the present work surveyed 200 patients in five different hospitals from December 2019 to February 2020.
UNASSIGNED: The current study revealed that most respondents (95 %) received PPIs for gastrointestinal indications while the rest were taking H2 receptor antagonists for their gastric ailments. Most patients taking PPIs alone (> 3 years; 95 % of respondents) claimed some unusual musculoskeletal side effects, such as weakness, flank pain, spasm of hands and feet, muscle aches, numbness, and tremor. About 61 % of patients taking PPIs experienced low back pain whereas the respondents with neck pain and knee joint pain were 10 % and 7 %, respectively. However, few osteopenia and osteoporotic incidences have been also recorded. Although further studies are required to confirm the impact of these antiulcerants on the bone, these patient responses suggest that these musculoskeletal side effects might have some links with altered bone metabolism.
UNASSIGNED: It is possible that anti-ulcerant therapies may worsen the bone metabolism of patients suffering from osteoporosis or other bone disorders, and awareness and precautions should be raised among the patients and clinicians for the careful administration of PPIs to patients suffering from bone disorders.